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In Brief
Eichenlaub et al. examine gene
expression changes during the transition
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lactate dehydrogenase as a key driver of
neoplasia in a Drosophila EGFR model.
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diet also drive neoplasia. Synergy
between EGFR and LDHA correlates with
poor clinical outcome in some human
cancers..
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Cancers develop in a complex mutational landscape.
Genetic models of tumor formation have been used
to explore how combinations of mutations cooperate
to promote tumor formation in vivo. Here, we identify
lactate dehydrogenase (LDH), a key enzyme in War-
burg effect metabolism, as a cooperating factor
that is both necessary and sufficient for epidermal
growth factor receptor (EGFR)-driven epithelial
neoplasia and metastasis in a Drosophila model.
LDH is upregulated during the transition from hyper-
plasia to neoplasia, and neoplasia is prevented by
LDH depletion. Elevated LDH is sufficient to drive
this transition. Notably, genetic alterations that in-
crease glucose flux, or a high-sugar diet, are also suf-
ficient to promote EGFR-driven neoplasia, and this
depends on LDH activity. We provide evidence that
increased LDHA expression promotes a transformed
phenotype in a human primary breast cell culture
model. Furthermore, analysis of publically available
cancer data showed evidence of synergy between
elevated EGFR and LDHA activity linked to poor clin-
ical outcome in a number of human cancers. Altered
metabolism has generally been assumed to be an
enabling feature that accelerates cancer cell prolifer-
ation. Our findings provide evidence that sugarmeta-
bolism may have a more profound role in driving
neoplasia than previously appreciated.
INTRODUCTION
Cancers develop in a complex mutational landscape [1]. Individ-
ual tumors carry hundreds, even thousands, of mutations. Spe-
cific tumor types have identifiable signatures, consisting of a
small number of relatively common ‘‘driver’’ mutations [2]. The
mutational spectrum can vary in different regions of any given tu-3220 Current Biology 28, 3220–3228, October 22, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://mor, indicating clonal heterogeneity [3, 4]. This heterogeneity
poses a challenge to identify which among the many mutational
changes contribute to disease.
Genetic models of tumor formation have been used to explore
how combinations of mutations can cooperate to promote
neoplasia [5–9]. Excess epidermal growth factor (EGF) receptor
activity is causally linked to many epithelial cancers, including
breast cancer [2, 10, 11]. In Drosophila tumor models, EGF re-
ceptor (EGFR) overexpression drives hyperplastic growth, but
the tissue does not normally progress to neoplasia [12]. When
combined with additional genetic alterations, the hyperplastic
imaginal disc tissues can undergo neoplastic transformation
and metastasis [12–14]. Interestingly, specific genetic combina-
tions produce tumors with different phenotypic characteristics,
suggesting that these models may provide the means to explore
specific cancer phenotypes.
A growing body of evidence has suggested an association
between altered sugar metabolism and cancer risk [15–18]. In
cancer cells, glucose metabolism shifts away from using pyru-
vate to feed oxidative phosphorylation toward use of lactate in
aerobic glycolysis (the Warburg effect). The lactate dehydroge-
nase enzyme plays a key role in the shift to Warburg meta-
bolism. Altered metabolism is thought to enhance the growth
potential of cancer cells by diverting glucose to produce build-
ing blocks for increased biomass in the form of amino acids,
at the expense of efficiency in ATP production via the tricarbox-
ylic acid (TCA) cycle [19]. Depletion of lactate dehydrogenase
(LDH) can reduce tumorigenesis in EGFR (Neu)-dependent
breast cancer as well as c-Myc-mediated transformation [20,
21], indicating an important role for this metabolic shift. LDH
was found to be upregulated in a Drosophila tumor model driven
by overexpressing the activated vascular endothelial growth
factor (VEGF) or platelet-derived growth factor (PDGF) receptor,
Pvr [22], but its contribution to tumor formation was not as-
sessed. In this report, we identify LDH as a cooperating factor
that is both necessary and sufficient for EGFR-driven epithelial
neoplasia in vivo. Genetic alterations that increase glucose
flux, or a high-sugar diet, were sufficient to promote EGFR-
driven neoplasia, and this depends on LDH. These findings
provide evidence that Warburg effect metabolism may have author(s). Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. LDH Activity Required for EGFR-Induced Tumor Formation
(A) Confocal micrographs of wing imaginal discs expressing UAS-EGFR+UAS-GFP alone or together with UAS-psqRNAi to deplete psq. Transgenes were
activated using apGal4 andGal80ts to control the timing of transgene expression, as described [13]. Discs were labeledwith antibody to DE-cadherin (red) to label
apical junctional complexes and DAPI (blue) to show the tissue. Samples were collected at 12 hr, 4 days, and 8 days after transgene induction for the
EGFR+psqRNAi genotype and at 12 hr and 4 days for EGFR alone. The scale bars represent 100 mm. See Figure S1A for quantification. See Figure S2 for relevant
transcript expression data. See Table S1 for list of genes upregulated in neoplasia. See also Figure S3 for lactate measurement.
(B) Unsupervised principal-component analysis illustrating that replicate samples cluster together. PCA shows biological group separation according to time
progression (1st component) and genetic background (2nd component; red versus green). The first two components account for 58% of variation in the data.
(C) Heatmap illustrating expression levels of the most important genes contributing to the 1st and 2nd PCA components. See Figure S2A for expression data on
metabolic pathways.
(D) Imaginal discs expressing UAS-EGFR+UAS-psqRNAi with UAS-GFP or UAS-LDHRNAi under apGal4 control to deplete LDH activity. Note the reduced size of
the LDH depleted tissue.Middle panels show optical cross sections of discs labeled with anti-DE-cadherin. Right panels show other discs of the same genotypes
labeled with antibody to MMP1 (red) and DAPI. The scale bars represent 100 mm.
See Figure S1B for quantification. Controls for RNAi are in Figure S2.more fundamental role in driving neoplasia than previously
appreciated.
RESULTS
In Drosophila imaginal discs, EGFR overexpression drives hy-
perplastic growth, but the tissue does not progress to neoplasia
andmetastasis. When combined with depletion of the chromatin
regulator pipsqueak (psq), the hyperplastic imaginal disc tissue
loses epithelial polarity, undergoes neoplastic transformation,
and forms metastases [13]. To examine transcriptional changes
during progression from hyperplasia to neoplasia, we examineda time course of progression after transgene induction in wing
imaginal discs. At 4 days after transgene induction, both EGFR
and EGFR+psqRNAi genotypes produce hyperplastic tissue
with overall normal epithelial organization, with normal apico-
basal polarity (Figure 1A; quantification in Figure S1A). By
8 days, the EGFR+psqRNAi discs have almost completely lost
epithelial organization and continued to grow (Figures 1A and
S1A), whereas those expressing EGFR alone have stopped
growth and the larvae undergone pupariation.
RNA expression profiles were compared from imaginal discs
expressing EGFR with or without the psqRNAi transgene to
deplete psq. Samples were collected in quadruplicate at 12 hrCurrent Biology 28, 3220–3228, October 22, 2018 3221
and 4 days for the EGFR-expressing control hyperplastic tissue
and at 12 hr, 4 days, and 11 days for the EGFR+psqRNAi tumor
samples (Figure 1A). The EGFR control and EGFR+psqRNAi sam-
ples were very similar at the 12-hr time point (Figures 1B and 1C).
The EGFR+psqRNAi samples were different from the EGFR sam-
ples at 4 days and becamemore so by 11 days, with a set of tran-
scripts showing progressive upregulation in the EGFR+psqRNAi
samples (Figures 1B and 1C). While this work was in progress,
Wang et al. [22] reported that Ecdysone-inducible gene L3
(ImpL3), which encodes Drosophila LDH, was upregulated along
with other enzymes involved in glucose metabolism in a
Drosophila tumor model driven by overexpressing the activated
VEGF or PDGF receptor, Pvr. LDHwas among the most upregu-
lated genes in our 11-day EGFR+psqRNAi tumor samples (log2
fold change 2.5; adjusted p value 0.001), along with several
other genes involved in glucose and pyruvate metabolism
(Figure S2A).
To test the contribution of LDH upregulation in the EGFR+
psqRNAi tumor model, we co-expressed an upstream activating
sequence (UAS)-RNAi transgene to selectively deplete LDH.
The ability of the RNAi transgene to offset upregulation of LDH
transcript in the EGFR+psqRNAi model was confirmed by qRT-
PCR (Figure S2B). We also confirmed that depleting LDH alone
had little or no effect on growth of normal tissue (Figure S1C).
Depletion of LDH reduced tumor growth (Figures 1D and S1B)
and restored normal epithelial organization in EGFR+psqRNAi tu-
mors, visualized by restored apical localization of the epithelial
polarity marker DE-cadherin (Figure 1D). We confirmed that
elevated LDH expression in these tumors correlated with an in-
crease in lactate production and that depletion of LDH transcript
offset this increase (Figure S3). Other transcripts tested had no
effect on tumor formation in the EGFR+psqRNAimodel (Table S1).
Loss of epithelial organization and matrix metalloproteinase 1
(MMP1) expression are typically associated with transformation
and invasiveness of human epithelial cancers and correlate with
metastatic potential in imaginal disc tumor models [12, 23, 24].
We noted a strong reduction in the amount of MMP1 expression
in the LDH depleted tissue, compared to the tissue expressing
EGFR+psqRNAi alone (Figure 1D). These findings suggest that
LDH activity is required for the neoplastic transformation of the
epithelial tissue in the EGFR+psqRNAi model. It is noteworthy
that depletion of LDH did not affect growth in another epithelial
tumor model based on removing scribble, although LDHwas up-
regulated in those tumors [25].
LDH Drives Neoplasia
A more detailed look at LDH transcript using qPCR showed a
progressive increase in LDH levels in tissue expressing EGFR+
psqRNAi. At 4 days, when the tissue was hyperplastic in
morphology, the difference was 2-fold (Figure 2A). By 8 days,
this increased >10-fold, as the tissue became neoplastic (Fig-
ure 2A). The finding that LDH expression was strongly upregu-
lated during the transition from hyperplastic to neoplastic growth
prompted us to ask whether LDHmight be sufficient to push hy-
perplastic tissue into neoplasia. To address this, we used an EP
line (a P element containing UAS sequences for Gal4 driven acti-
vation) inserted at the endogenous ImpL3 gene to allow Gal4-
dependent regulation of LDH (overexpression was confirmed
by qPCR; Figure S2B). Although expression of UAS-LDH on its3222 Current Biology 28, 3220–3228, October 22, 2018own caused a small reduction in average disc size (Figures 2B
and S1D), co-expression of LDH with EGFR led to the formation
of large tumors with elevatedMMP1 expression compared to the
EGFR control (Figures 2C, 2D, and S1E). The EGFR+LDH tumors
also showed loss of epithelial polarity, visualized by loss of polar-
ized DE-cadherin (Figure 2E). These tumors also showed disrup-
tion of the integrity of the basement membrane, visualized by
loss of perlecan expression (Figure 2F). Interestingly, co-expres-
sion of LDH with the Hippo pathway transcriptional coactivator,
Yorkie, or with an activated form of Notch also promoted tumor
formation (Figure S1F). In each case, the underlying growth
driver did not produce neoplasia on its own but can be pushed
toward a more aggressive state by increased LDH activity.
Increased Glucose Intake Promotes Neoplasia
Glycolysis is considerably less efficient than oxidative phosphor-
ylation in terms of ATP yield per molecule of glucose. To
compensate for this, cancer cells increase glucose uptake by
upregulating glucose transporters, including GLUT1 [26, 27]. In
this context, it was interesting that Glut1 transcript levels were
lower in the neoplastic EGFR+psqRNAi tumors compared to hy-
perplastic discs (Figure S2C). To test the effect of increased
glucose flux, we expressed the EGFR transgene with and
without a UAS-Glut1 transgene. Increasing Glut1 expression
on its own had only a limited effect on disc size (Figure S1G),
but when co-expressed with EGFR, Glut1 produced massively
overgrown imaginal discs (compare Figure 3A with 3C and 3E
with 3F; measurements in Figure S1G). We observed the same
effect by rearing the EGFR-expressing larvae on a high-sugar
diet (compare Figure 3Awith 3D and 3Ewith 3H and 3I; measure-
ments in Figure S1H). Downregulation of Glut1 might reflect a
regulatory feedback mechanism designed to limit sugar uptake
when the pyruvate shunt is active. This appears to protect
against neoplasia. Indeed, further depletion of Glut1 by RNAi
treatment strongly reduced growth of the EGFR+psqRNAi tumors
(Figure S1I).
Co-expression of UAS-Glut1 with UAS-EGFR led to loss of
epithelial polarity, shown by delocalization of apical DE-cadherin
(Figures 3E and 3F), but this was largely restored to normal by
depleting LDH in this background (Figure 3G), and disc size
was reduced toward normal (Figure S1G). Rearing larvae on a
high-sugar diet was not in itself sufficient to compromise epithe-
lial polarity, but when EGFR-expressing larvae were fed high
sugar, polarity was lost (Figures 3H and 3I). Again, polarity was
restored by LDH depletion in the high-sugar model (Figure 3J),
and disc size was reduced (Figure S1G). In both cases, the ef-
fects of elevated sugar flux are mediated via LDH activity, sug-
gesting a link to aerobic glycolysis. In a different Drosophila
genetic model, a high-sugar diet increased the aggressiveness
of tumors produced by expression of oncogenic Ras and activa-
tion of Src [28]. In this model, the transformed tissue responds to
high sugar by promoting insulin sensitivity. The mechanism ap-
pears to be different from the EGFRmodel in which downregula-
tion of Glut1 appears to form part of a feedback mechanism to
limit sugar flux via the pyruvate shunt.
Our findings provide evidence that elevated sugar flux can
drive cells toward a neoplastic phenotype. We noted that
animals with increased LDH activity, animals with increased
Glut1 expression, and those fed with increased dietary sugar
Figure 2. LDH Cooperates with EGFR to Drive Neoplastic Tumor Formation
(A) LDHmRNAmeasured by qPCR. apGal4was used to drive UAS-EGFR + UAS-psqRNAi for 4, 8, and 12 days. Control is apGal4 + UAS-GFP at 4 days. The data
show mean ± SD from three technical replicates of a representative experiment. Comparable results were obtained in independent experiments. Data were
normalized to aTub84B.
(B) apGal4-driven expression of an EP-transgene insertion at the Impl3 locus was used to direct LDH expression. LDH overexpression was verified by qPCR (see
Figure S2B).
(C and D) Discs expressing EGFR alone (C) or with LDH (D) under apGal4 control. Discs were labeled with antibody toMMP1 (red), DAPI, andGFP. See Figure S1D
for size measurements.
(E and F) Discs expressing EGFR, GFP, and LDH.
(E) Optical cross section (XZ) labeled with antibody to DE-cadherin and DAPI.
(F) XY and XZ optical sections labeled with GFP, DAPI, and antibody to perlecan to label the basement membrane. Arrows indicate gaps where the basement
membrane has broken down.
Scale bars represent 100mm.contained small patches of GFP-expressing tissue in their body
cavity, at some distance from the primary tumorous imaginal
disc (boxed regions shown at higher magnification in Figures
3A–3D). In light of the loss of epithelial organization under these
conditions, it is tempting to speculate that these may represent
metastatic lesions originating from the primary tumor as a conse-
quence of cellular transformation induced by high levels of aero-
bic glycolysis.
LDH Promotes a Transformed Phenotype in a Human
Breast Cancer Model
A previous study reported that increased GLUT3 expression
increased the transformed phenotype in a 3D breast cancer cul-
ture model [29]. We asked whether elevated LDH activity was
sufficient to promote a transformed phenotype using a breast
epithelial cell line derived from normal tissue. HTM3522 cells
were transduced to express human LDHA or with a control vec-
tor and assayed in culture and in a 3D matrix. In 2D culture, cells
overexpressing LDHA become spindle shaped and formed
fewer coherent islets (Figure 4A). These shape changes are remi-
niscent of an epithelial-mesenchymal transition. Consistently,
LDHA was among the RNAs reported to be upregulated inMCF10A breast cancer cells undergoing epithelial-mesen-
chymal transition (EMT) [30]. In 3D culture, cells treated with
the control vector formed tight acinar spheres, with normal
apico-basal polarity (apical inward, visualized by labeling with
the Golgi marker GM130; Figures 4B and 4C). This polarized or-
ganization was lost in 1/3 of the samples expressing LDHA
(Figures 4B–4D). This difference was statistically significant
(p = 0.0158; odds ratio 2.07 using Fisher’s exact test).
Interestingly, increased glucose transporter levels have been
reported to promote a transformed phenotype, reducing epithe-
lial polarization in 3D cultures of breast cancer cells, and these
phenotypes were suppressed by lowering glucose transporter
levels [29]. Together with our findings, this study prompted us
to ask whether increased sugar flux through the glycolytic
pathway might be linked to poor clinical outcome in human
cancers.
Synergy between LDHA and EGFR in Human Cancer
To examine links between LDH and EGFR in human cancers, we
made use of publically available data from The Cancer Genome
Atlas (TCGA). 20 cancer types had RNA sequencing data avail-
able for at least 100 patients and sufficient clinical follow-up toCurrent Biology 28, 3220–3228, October 22, 2018 3223
Figure 3. High Sugar Causes Neoplasia in EGFR-Expressing Discs
(A–D) Images of whole larvae expressing UAS-EGFR and UAS-GFP under apGal4 control. Shown are Ap-Gal4+UAS-EGFR (A), Ap-Gal4+UAS-EGFR+UAS-LDH
(B), Ap-Gal4+UAS-EGFR+UAS-Glut1 (C), and Ap-Gal4+UAS-EGFR (D) fed on high sugar diet.
(B–D) Co-expressing EP-LDH (B); co-expressing UAS-Glut1 (C) fed on a high-sugar diet (D). The boxed area is shown magnified at right in each panel.
(E–G) Imaginal discs from larvae expressing UAS-EGFR and UAS-GFP under apGal4 control. Shown are Ap-Gal4+UAS-EGFR (E), Ap-Gal4+UAS-EGFR+UAS-
Glut1 (F), and Ap-Gal4+UAS-EGFR+UAS-Glut1+ UAS-LDHRNAi (G).
(F) Co-expressing UAS-Glut1.
(G) Co-expressing UAS-Glut1 and UAS-LDHRNAi. See Figure S1G for size measurements.
(H and I) apGal4 alone (H) or expressing UAS-EGFR (I) and fed on a high-sugar diet.
(J) apGal4 + UAS-EGFR co-expressing UAS-LDHRNAi and fed on a high-sugar diet. See Figure S1H for size measurements. See Figure S3 for Glut1 mRNA PCR.
Scale bars represent 100mm.reveal disease progression in at least 10% of patients. These
cancers were selected for analysis (patient information is sum-
marized in Table S2). Human LDH enzymes are encoded by 4
genes. The LDHA isoform favors conversion of pyruvate to
lactate, whereas LDHB favors conversion of lactate to pyruvate.
LDHA expression is elevated in many cancers due to hypoxia-3224 Current Biology 28, 3220–3228, October 22, 2018induced upregulation, and LDHB is often downregulated [31].
We therefore determined the ratio of LDHA/LDHB expression
for each cancer type and divided the patient populations into 3
equal-sized groups (low, middle, and high). Next, we estimated
EGFR activity in these cancers using TCGA protein expression
data for total EGFR plus the pY1068 and pY1173 tyrosine
Figure 4. Elevated LDHA Compromises Polarity in Human Breast
Epithelia
Cells were transduced to express LDHA or with a control vector. LDHA
expression was verified by qPCR.
(A) Phase contrast imaging of monolayer cultures. The scale bar represents
100 mm.
(B) Phase contrast imaging 3D Matrigel cultures. The scale bar represents
50 mm.
(C) Immunostaining with the Golgi marker GM130 (green). Nuclei were labeled
with DAPI (blue). The scale bar represents 50 mm.
(D) Graphs show the mean value of the percentage of apically polarized
structures in three separate experiments ± SD.phosphorylated forms of EGFR and divided the patients in
groups based on EGFR level. Where patient numbers were insuf-
ficient for 3 groups, low versus high groups were used, as indi-
cated in Table S2.
To test the hypothesis that there might be synergy between a
shift toward high LDHA/B ratio and elevated EGFR activity, we
performed a multivariate regression analysis and calculated
the hazard ratio (HR) for synergistic effects progression. In thecase of three cancer types (breast cancer [BRCA estrogen re-
ceptor (ER)/progesterone receptor (PR) negative], sarcoma
[SARC], and lower grade glioma [LGG]; Figure 5A), there was a
significant effect on progression-free survival, as indicated by
the increasedHR. For these three cancer types, we plotted an ef-
fect size for LDHA/B ratio, EGFR levels, and the combined ef-
fects separately (Figures 5B–5D). For all 3 cancer types, the
patient subgroup with both high EGFR levels and high LDHA/B
ratio showed an increased HR, and those with middle or low
levels did not (Figures 5B–5D). For LGG, high EGFR and high
LDHA/B ratio had no effect on their own. Interestingly, for sar-
coma, the high EGFR group on its own showed a reduced hazard
ratio but clearly synergized with high LDHA/B ratio to result in a
worse outcome (Figure 5C). The breast cancer patients were
placed into two groups due to the lower number of hormone-re-
ceptor-negative patients with clinical events. Notably, the high
LDHA/B group on its own showed a reduced hazard ratio but
clearly synergized with high EGFR to result in a worse outcome
(Figure 5D). These findings provide evidence that patients with
both higher LDHA activity and higher EGFR activity show earlier
disease progression in breast cancer, sarcoma, and lower grade
gliomas.
DISCUSSION
In this report, we identify the LDH enzyme as a critical factor
driving the transition from benign hyperplastic growth to
neoplasia and metastasis in an EGFR-dependent Drosophila
epithelial tumor model. LDH upregulation was needed for
EGFR-dependent neoplasia. Moreover, LDH overexpression
was sufficient to drive neoplasia in combination with EGFR
expression. Overexpression of LDHA in a human primary breast
cancer cell model promoted a more transformed cellular
phenotype. The possible significance of synergy between high
LDH in a background of high EGFR activity in human cancer
is supported by our analysis of TCGA datasets: we report evi-
dence that patients with higher LDHA activity and higher EGFR
activity show earlier disease progression in breast cancer, sar-
coma, and lower grade gliomas. These effects were only seen
when the two factors occurred together, suggesting synergy be-
tween EGFR activity and the metabolic shift toward aerobic
glycolysis.
While this manuscript was in preparation, another study re-
ported that increases in LDHA were able to promote EMT and
invasiveness in renal clear cell carcinoma (ccRCC) and that
blocking LDH activity could suppress these phenotypes as
well as metastasis of ccRCC in xenografts [32]. Although we
find no evidence for an effect of LDHA alone or of LDHA/EGFR
synergy in the TCGA ccRCC data, these findings merit further
attention.
The observations reported here provide evidence that
increased sugar flux, whether dietary or due to increased ab-
sorption, can promote neoplastic transformation of EGFR-ex-
pressing epithelial tissue. The underlying metabolic changes
appear to elicit these effects via the lactate shunt, because the
effects of high sugar were abrogated by lowering the level of
LDH expression in the tissue. A number of recent studies have
begun to link elevated sugar flux to the metastatic phenotype
[29, 32]. Together with our findings, these studies may provideCurrent Biology 28, 3220–3228, October 22, 2018 3225
Figure 5. LDH Activity Synergizes with EGFR in Human Cancers
Forest plots representing multivariate Cox proportional hazard regression models, illustrating variable effect size on progression-free survival. Filled squares
represent the hazard ratio (HR); lines represent the confidence interval.
(A) Forest plot showing HR for the synergy between increased LDHA/LDHB ratio and increased EGFR levels.
(B–D) Forest plots showing HR for increased LDHA/LDHB ratio and EGFR levels independently and when interacting. Shown are LGG (B), SARC (C), and
BRCA (D).
Vertical line, reference line; x axis, log2 hazard ratio and confidence interval; y axis, abbreviation for TCGA cancer type. Data were adjusted for histopathological
parameters as indicated in Table S2.a molecular framework to better understand the links between
diet, obesity, and cancer [16–18] and may help to select patient
populations who might benefit from future therapeutic agents
targeting lactate dehydrogenase activity.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Drosophila melanogaster strains
ap-Gal4,UAS-EGFR,UAS-Glut1,UAS-yki,UAS-Ni,UAS-DC8-GFP,UAS-LDH
RNAi and EP-LDHwere obtained from the Bloomington
Drosophila Stock Center. The Vienna Drosophila RNAi Center provided UAS-psqRNAi (no. 106404). UAS-Glut1 was from Marie-
There`se Besson [35]. UAS-Ni was from Marco Milan [36]. Flies were raised on medium containing agar (8 g/l), Brewer’s yeast
(23.6 g/l), dextrose (50.8 g/l) and corn meal (58 g/l). For the high sugar diet, 75 g of sucrose/l were added to the basic recipe. Flies
were raised at 25C in plastic vials on a 12h/12h light dark cycle, in a controlled humidity environment, except for those used in tem-
perature controlled Gal4 experiments as specified below. Tumors samples were collected frommature third instar larvae. The sex of
the larvae was not determined. The Health/immune status cannot be determined for individual larvae. Larvae were not subjected to
previous procedures. Larvae were drug and test naive.
Genotypes of experimental models
Figure 1
(A) ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+
(B) EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+; and EGFR + Psq-RNAi corresponds to ap-Gal4,
UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+
(D) EGFR + psqRNAi + GFP corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; and EGFR +
psqRNAi + LDHRNAi corresponds to ap-Gal4, UAS-psqRNAi/+; UAS-EGFR, tub-Gal80ts/UAS-LDHRNAi
Figure 2
(A) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EGFR + psqRNAi corresponds to ap-Gal4, UAS-psqRNAi/
UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+
(B) ap > LDH corresponds to ap-Gal4, UAS-CD8-GFP; tub-Gal80ts/EP-LDH; control corresponds to yw.
(C) ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+
(D-F) ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/EP-LDH
Figure 3
(A, D, E, I) ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+
(B) ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/EP-LDH
(C, F) ap-Gal4, UAS-CD8-GFP/UAS-Glut1; UAS-EGFR, tub-Gal80ts/+
(G) ap-Gal4, UAS-CD8-GFP/UAS-Glut1; UAS-EGFR, tub-Gal80ts/UAS-LDHRNAi
(H) ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+
(J) ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/UAS-LDHRNAi
Figure S1
(A) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-
EGFR, tub-Gal80ts/+; and EGFR + PsqRNAi corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+
(B) EGFR + PsqRNAi corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; EGFR + psqRNAi + LDHRNAi
corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/UAS-LDHRNAi
(C) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; LDHRNAi corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-
Gal80ts/UAS-LDHRNAie2 Current Biology 28, 3220–3228.e1–e6, October 22, 2018
(D) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EP-LDH corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-
Gal80ts/EP-LDH
(E) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-
EGFR, tub-Gal80ts/+; EGFR + LDH corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/EP-LDH
(F) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; Yki corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-Yki,
tub-Gal80ts/+; Yki + LDH corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-Yki, tub-Gal80ts/EP-LDH; Ni corresponds to ap-Gal4,
UAS-CD8-GFP/+; UAS-Ni, tub-Gal80ts/+; Ni + LDH corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-Ni, tub-Gal80ts/EP-LDH
(G) Control corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-
EGFR, tub-Gal80ts/+; EGFR + Glut1 corresponds to ap-Gal4, UAS-CD8-GFP/UAS-Glut1; UAS-EGFR, tub-Gal80ts/+; EGFR +
Glut1 + LDHRNAi corresponds to ap-Gal4, UAS-CD8-GFP/UAS-Glut1; UAS-EGFR, tub-Gal80ts/UAS-LDHRNAi; and Glut 1 corre-
sponds to ap-Gal4, UAS-CD8-GFP/UAS-Glut1; tub-Gal80ts/+
(H) Control and control + sugar correspond to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/+; EGFR and EGFR + sugar correspond to
ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+; and EGFR + sugar + LDHRNAi correspond to ap-Gal4, UAS-CD8-GFP/+;
UAS-EGFR, tub-Gal80ts/LDHRNAi
(I) EGFR + PsqRNAi + GFP corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; and EGFR +
PsqRNAi + Glut1RNAi corresponds to ap-Gal4, UAS-psqRNAi/UAS-Glut1RNAi; UAS-EGFR, tub-Gal80ts/+
Figure S2
(A) E corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+; and EP corresponds to ap-Gal4, UAS-psqRNAi/UAS-
CD8-GFP; UAS-EGFR, tub-Gal80ts/+
(B) LacZ corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/UAS-lacZ; EGFR + Psqi + GFP corresponds to ap-Gal4, UAS-
psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; EGFR + Psqi + LDHi corresponds to ap-Gal4, UAS-psqRNAi/UAS-LDHRNAi;
UAS-EGFR, tub-Gal80ts/+; RFP corresponds to ap-Gal4, UAS-CD8-GFP/+; tub-Gal80ts/UAS-RFP; EP-LDH corresponds to ap-
Gal4, UAS-CD8-GFP/+; tub-Gal80ts/EP-LDH; EP-LDH + LDHi corresponds to ap-Gal4, UAS-CD8-GFP/UAS-LDHRNAi; tub-
Gal80ts/EP-LDH; EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+; EGFR + Psq-RNAi corresponds
to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; and control corresponds to ap-Gal4, UAS-CD8-GFP/+;
tub-Gal80ts/+
Figure S3
EGFR corresponds to ap-Gal4, UAS-CD8-GFP/+; UAS-EGFR, tub-Gal80ts/+; and EGFR + PsqRNAi hyperplastic and EGFR +
PsqRNAi neoplastic corresponds to ap-Gal4, UAS-psqRNAi/UAS-CD8-GFP; UAS-EGFR, tub-Gal80ts/+; and EGFR + psqRNAi +
LDHRNAi ap-Gal4, UAS-psqRNAi/UAS-LDHRNAi; UAS-EGFR, tub-Gal80ts/+;
Controlled Overgrowth using Gal80ts
The Gal4/Gal80 system was used to allow conditional transgene activation in order to bypass early lethality due to expression of
EGFR+psqRNAi. Embryos were collected for 24h (for microarray experiments) or 48h (for immunostaining) at 18C and were allowed
to develop at 18C tomaintainGal80-dependent repression ofGal4 until the larvae reached early third instar (5 days for immunostain-
ing or 7 days for microarray experiments). Larvae were then transferred to 29C to induce Gal4 and raised for the indicated times.
Larval gender was not considered.
Cell lines
HTM3522 breast epithelial cells (female) were cultured in H14 medium consisting of DMEM:F12 with 2 mM glutamine containing
250ng/mL insulin, 10ng/mL EGF, 10mg/mL transferrin, 2.6ng/mL sodium selenite, 1010 M estradiol, 1.4x106 M hydrocortisone
and 5mg/mL prolactin as described [42].
Phoenix-Ampho cells were purchased from American Type Culture Collection. These were not further authenticated.
METHOD DETAILS
RNA extraction and microarrays
Approximately 20 pairs of wing discs were dissected and processed for total RNA extraction using Trizol (Life Technologies). RNA
was prepared from dissected imaginal discs from four replicates of each of the five conditions: EGFR and EGFR+psqRNAi at 12 hr;
EGFR and EGFR+psqRNAi samples at day 4, and from EGFR+psqRNAi at day 11 of tumor growth. Expression profiling was performed
with Genechip Drosophila Genome 1.0 Arrays (Affymetrix) by the Genomics Core Facility at European Molecular Biology Laboratory
(Heidelberg, Germany). Samples were blinded to the Genomics Core Facility for profiling.
Microarray data analysis
Microarray data analysis was performed using R(3.4.3)/Bioconductor [37]. Robust Multi-array Average (RMA) algorithm [43, 44] was
used to normalize variation between arrays and within probe sets and to improve data distribution by log2 transformation of intensity
values as implemented in oligo (1.42.0) package in Bioconductor R (http://www.bioconductor.org/packages/release/bioc/html/
oligo.html [38],). For downstream analysis control, background and spike-in probes were removed. As well as genes whose expres-
sion was below background detection threshold in at least 4 samples. Threshold was defined as 80% of anti-genomic (backgroundCurrent Biology 28, 3220–3228.e1–e6, October 22, 2018 e3
hybridization) probe intensity’s. This is important since expression estimate may not be a reliable for these genes. To ask if the gene
expression data separated samples according to biological groups, principal component analysis (PCA) was applied to scaled log2
data. We used the ‘‘FactoMineR’’ (1.40) package with default options [[39]]. Genes that exhibited variation in expression levels be-
tween time points or genetic groups were selected for PCA analysis (based on linear model fit; adj.p.val < 0.05)(Limma; 3.34.9 [40]).
This removes non-informative signals. Genes that contributed to first (time) and second (groups) component (> 0.025) were selected
and their expression levels were visualized as a heatmap. Data was scaled and centered relative to control samples. Genes differ-
entially expressed in 4d versus 11d EGFR+psq RNAi tumors were identified using ‘‘Limma’’ package with default settings. A gene was
considered differentially expressed when the Bonferroni corrected P value was < 0.05 and the log2 fold change > 1.5.
Metabolic pathway status was assessed by examining gene signatures associated with KEGGmaps; Glycolysis/Gluconeogenesis
(above phosphoenolpyruvate); TCA cycle; Fructose and mannose metabolism; Oxidative phosphorylation (first 4 complexes); Pyru-
vatemetabolism; Fatty acid biosynthesis; Fatty acid degradation. Normalized gene expression data was scaled and centered relative
to control samples.
Quantitative PCR
20 wing imaginal discs from 3rd instar larvae were dissected in ice-cold PBS and were incubated in 1000 ml TRIzol (Invitrogen) for
5 min at room temperature. After the addition of 200 ml Chloroform, samples were vortexed vigorously for at least 15 s and incubated
at room temperature for 3 min. The sample was centrifuged at 12000 g for 15 minutes at 4C. Following centrifugation, the mixture
separated into lower red, the phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. RNA remains exclu-
sively in the aqueous phase. The upper aqueous phase (350 ml) was carefully transferred into fresh tube without disturbing the inter-
phase. The RNA was precipitated from the aqueous phase by mixing it with 500 ml isopropyl alcohol. After 10 min incubation at room
temperature, the sample was centrifuged at 12000 g for 10 min at 4C. The RNA precipitate, often invisible before centrifugation,
forms a gel-like pellet on the bottom of the tube. The pellet is washed with 1ml 75% ethanol. After centrifugation (7500 g, 5 min,
4C), supernatant is removed completely and the pellet is air-dried for 5-10 min. RNA is resuspended in 30 ml sterile water. Up to
3 mg total RNA was treated with RQ1 DNase I (Promega) and reverse-transcribed using the SuperScript III Reverse Transcriptase
Kit and oligo(dT) Primer. For RNA denaturation, 1 ml of the primers, 1 ml 10mMdNTPs and the DNase-treated RNAwere first incubated
in a reaction volume of 13 ml for 5 min at 65C and cooled down on ice. Next, 4 ml 5x First-Strand Buffer, 1 ml 0.1 M DTT, 1 ml of
RNaseOUT RNase Inhibitor and 1 ml Superscript III RT (200 units/ml) were added. The reaction mix was incubated at 50C for
60 min and inactivated at 70C for 10 min. Real-time quantification was performed using SsoFastTM EvaGreen reagents (Bio-
Rad) on QuantStudio 6 Flex Real-Time PCR System (Applied Biosystem). Primer Sequences:
aTub84B forward: TGGGCCCGTCTGGACCACAA
aTub84B reverse: TCGCCGTCACCGGAGTCCAT
LDH forward: GCTGGTAGAGTACAGTCCCG
LDH reverse: GGACGAGTCCAAGTTGGTG
Glut1 forward: ACCGATTGGCTAACTGCATC
Glut1 reverse: CAGACAGGTGGAGGCTGAC
Samples were not blinded. No data were excluded.
Immunostaining
Primary antibodies: rabbit anti-Perlecan (provided by Stefan Baumgartner [33]); anti-DE-Cadherin, and mouse anti-MMP1 (3A6B4/
5H7B11/3B8D12 antibodies weremixed in equal amounts) were fromDevelopmental Studies HybridomaBank. Alexa Fluor 635 phal-
loidin was used to label F-actin (Life Technologies). Third-instar larvae were dissected in PBS and fixed in 4% formaldehyde/PBS for
20’ RT then washed three times for 10’ in 0.1%Triton/PBS (PBT) and blocked for 30’ in 3% BSA in PBT, 5mM NaCl (BBT). Samples
were incubated at 4C overnight with primary antibody diluted in BBT, washed three times for 15’ in BBT, and incubated with fluo-
rescent secondary antibody and DAPI for 1h RT. After four 15’ washes with PBT, discs were mounted in 90% glycerol and PBS
containing 0.05% N-Propyl Gallate. Samples were not randomized or blinded. Key experiments were repeated several times by 2
investigators with independent crosses over a period of years with consistent results. Samples were not blinded. For quantification,
at least 10 larvae were dissected and analyzed as described below.
LDHA expression, cell culture, viral transduction
The LDHA-expressing construct was cloned by PCR using cDNA from HMT3522 cells into the pBabe (puro) expression vector with
the primers ATGCAGATCTAATATGGCAACTCTAAAGGATC and GCGAGTCGACTTAAAATTGCAGCTCCTTTTGG. The plasmid was
sequenced to verify the ORF (NM_005566). Phoenix-Ampho cells were cultured in DMEM media. Amphotropic retroviruses were
made as described previously [45]. Viral particles-containing supernatant from transfected Phoenix-Ampho cells was harvested
at 36–48 hr. HMT3522 cells were plated in H14 media 24 hours before being infected with viruses expressing LDHA or control empty
vector overnight in the presence of 8 mg/ml polybrene. Puromycin (1mg/ml) selection was started at 36 hours and stable cells were
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3D Epithelial polarization assay
In monolayer culture, the HTM3522 breast epithelial cells were propagated on collagen coated culture vessels (Purecol; Advanced
BioMatrix, San Diego, CA). Transductions were performed at passage 38. HMT3522-LDHA+ and HMT3522-EV were trypsinized to
single cells frommonolayer cultures and 1x105 cells were embedded in 300mLMatrigel (BDBiosciences) in 24well dishes in triplicate.
From day 7 EGF was omitted from the H14 culture medium [46]. At day 12 the 3D gels were briefly dehydrated and snap frozen
in 80 hexane. 10mm sections were cut on a cryostat with an interval of R 30mm and fixed in 3.5% formalin, methanol/acetone
1:1 and 0.1% Triton X-100 for 5 min followed by staining with an antibody to the Golgi marker GM130 (clone 35/GM130, diluted
1:50/1:15, BD Biosciences) and visualized utilizing the Ultravision ONE Detection System (Thermo Fisher) for quantification, or by
immunofluorescence with Alexa Flour 488 goat anti-mouse secondary antibodies (Invitrogen). The fraction of polarized structures
was determined by evaluating structures consisting of > 4 cells in sections and scoring for the orientation of the GM130 staining
as toward the lumen (polarized) or scattered (non-polarized). One hundred structures were examined for each gel. Samples were
not blinded. No data were excluded.
Computational analysis of human tumor data
RNA sequencing data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) Genomic Data Commons
Data Portal (Data Release version 8.0) (https://gdc-portal.nci.nih.gov/), using the R package ‘‘TCGAbiolinks’’ [41]. Upper quartile
normalized fragments per Kb of transcript per million mapped reads data was used for the analyses. Cancer types were selected
by (1) RNA sequencing data available for at least 100 patients and (2) with sufficient follow-up to identify a clinical progression event
in at least 10%of patients. 20 cancer typesmet these criteria and Progression free survival was calculated using data downloaded on
17.08.2017 (Table S2). Next, reverse phase protein array data were downloaded from http://tcpaportal.org/tcpa/ on 12.10.2017.
Scaled level 4 relative protein levels of EGFR (Cell Signaling Technologies; 2232), EGFR_pY1068 (CST; 2234), EGFR_pY1173
(Abcam; ab32578) were summed to calculate an overall EGFR score. Acute Myeloid Leukemia did not have EGFR protein data,
andwas excluded from the analysis. Tomonitor the shift to LDHA activity we calculated the LDHA/LDHB expression ratio. For regres-
sion analysis patients were divided into equally sized groups (low, middle, high) based on overall EGFR score and on LDHA/LDHB
ratio (Table S2; Figure S4). Multivariate regression analysis with interaction term was used to examine the relationship between pro-
gression free survival, overall EGFR levels and the shift toward LDHAmetabolism [47]. The R package ‘‘Survival’’ was used to calcu-
late Hazard Ratio and associated p value (https://cran.r-project.org/web/packages/survival/index.html).
Lactate measurement
ECAR was monitored using real-time assessment with the Seahorse XFe96 Extracellular Flux Analyzer (Seahorse Biosciences-Agi-
lent Technologies, USA) as a measure of lactic acid release to the extracellular medium. wing discs of the indicated genotypes were
dissected in unbuffered DMEM (Sigma S5030) supplemented with 12mMglutamine (pH 7.4) and placed in a Seahorse 96-well micro-
plate (3 discs per well from control, EGFR, EGFR+psqRNAi+LDHRNAi larvae, or 2 discs per well from EGFR+psqRNAi). Experiments
were also conducted in Schneider’s Insect Medium (Sigma S9895) with similar results. Immediately after dissection, the plate
was centrifuged at 300xg for 3-5 min to pull-down the disks to the bottom of the wells, and the analysis was performed. Each mea-
surement cycle consisted of 1-minmix and 3-minmeasurement of the extracellular proton content. The analysis of lactate production
and release was initiated by three baseline ECAR measurement cycles. These were followed by the sequential injection of 10 mM
glucose to provide a substrate for cellular pyruvate production and subsequent lactate synthesis via LDH. Three ECARmeasurement
cycles were taken in between each injection and five final measurement cycles after the injection of 100 mM 2-Deoxyglucose to halt
glycolytic function and ensure that responses in ECAR are due to lactate release and exclude non-glycolytic extracellular acidifica-
tion. The pH of the reagents used during the test was adjusted to 7.4. The ECAR and OCR were recorded and calculated by the Sea-
horse XFe96 software, Wave. To normalize the data, the protein content for each well wasmeasured using the Pierce BCA assay with
BSA as standard. Samples were blinded to the Seahorse system operator.
QUANTIFICATION AND STATISTICAL ANALYSIS
Imaginal Disc Size Quantification
Images were taken using a Leica SP8 confocal microscope and analyzed using Fiji software and Adobe Photoshop. Images of whole
larvae were taken with a Leica M165 FC stereomicroscope equipped with GFP fluorescence optics. Images were processed with
ImageJ and Adobe Photoshop CC. The orientation and/or position of the wing discs were adjusted for consistent orientation in
the figures. No relevant information was affected. The original images are available on request. Wing imaginal discs of third instar
larvae were dissected and stained with DAPI. Whole wing disc area was determined with ImageJ, by setting the threshold to include
the whole DAPI-positive area with the option ‘‘Threshold.’’ The size of at least 10 discs per genotype was measured and statistical
significance was determined by using the Mann–Whitney U test with Bonferroni adjustment for multiple comparisons using Graph
Pad Prism. Data are in Figures S1 and S2. Many additional samples were visually examined, but not measured.
Hazard Ratio
The R package ‘‘Survival’’ was used to calculate Hazard Ratio and associated p value (https://cran.r-project.org/web/packages/
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size all groups were treated as ordered factors and adjusted for classical histopathology parameters as indicated in Table S2. Pa-
tients with complete information on time to an event, status, histopathology parameters used for adjustment, LDHA/LDHB expres-
sion levels and EGFR protein levels were included in the regression analysis. A linear Cox proportion hazard regression model with
‘‘contr. poly’’ contrast was used to calculate interaction hazard ratio and p value. Contrast was set to ‘‘contr.treatment’’ in order to
visualize the effect size for increase in overall EGFR level and increase in LDHA shift separately and for their interaction. Statistical
analyses were performed using R Software and results were visualized as forest plots using GraphPad Prism.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is GEO: GSE95613.e6 Current Biology 28, 3220–3228.e1–e6, October 22, 2018
